said Tuesday that its experimental cancer drug, Bexxar, has been scheduled for a review by an advisory panel to the Food and Drug Administration.
The Dec. 17 panel meeting is already a victory of sorts for Corixa, which has been hit with multiple delays in pushing Bexxar through the regulatory review process. Bexxar is being developed to treat non-Hodgkin's lymphoma.
Last March, the FDA issued a complete review letter on Bexxar, rejecting approval based on the need to conduct for additional studies to assess the drug's safety and efficacy. Corixa successfully appealed the FDA decision in June, leading to the new scheduled date for an advisory panel meeting.
is partnering on Bexxar's development.
Corixa shares were down 14 cents, to $8.75, in recent trading. Shares of
were also down 65 cents, to $45.69, because FDA approval of Bexxar will translate into competition for its already-approved non-Hodgkin's lymphoma drug, Zevalin.